The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Open accessAbstract
Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been identified in gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel enzymatic property of producing 2-hydroxyglutarate (2HG) from α-ketoglutarate. Here we report that 2HG-producing IDH mutants can prevent the histone demethylation that is required for lineage-specific progenitor cells to differentiate into terminally differentiated cells. In tumour samples from glioma patients, IDH mutations were associated with a distinct gene expression profile enriched for genes expressed in neural progenitor cells, and this was associated with increased histone methylation. To test whether the ability of IDH mutants to promote histone methylation contributes to a block in cell differentiation in non-transformed cells, we tested the effect of neomorphic IDH mutants on adipocyte differentiation in vitro. Introduction of either mutant IDH or cell-permeable 2HG was associated with repression of the inducible expression of lineage-specific differentiation genes and a block to differentiation. This correlated with a significant increase in repressive histone methylation marks without observable changes in promoter DNA methylation. Gliomas were found to have elevated levels of similar histone repressive marks. Stable transfection of a 2HG-producing mutant IDH into immortalized astrocytes resulted in progressive accumulation of histone methylation. Of the marks examined, increased H3K9 methylation reproducibly preceded a rise in DNA methylation as cells were passaged in culture. Furthermore, we found that the 2HG-inhibitable H3K9 demethylase KDM4C was induced during adipocyte differentiation, and that RNA-interference suppression of KDM4C was sufficient to block differentiation. Together these data demonstrate that 2HG can inhibit histone demethylation and that inhibition of histone demethylation can be sufficient to block the differentiation of non-transformed cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
In the citing paper
“In addition to its epigenetic effects, D-2HG inhibits enzymes from the canonical metabolic network (104). Such enzymes include transaminases that produce glutamate for glutathione biosynthesis, rendering IDH-mutant gliomas susceptible to treatments that deplete glutamate and enhance oxidative stress (105).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [104]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [118]
In the citing paper
“a neomorphic mutation in IDH1 and/or IDH2 causes a change in enzymatic activity and the accumulation of 2-hydroxyglutarate (2-HG), which inhibits the function of αKG-dependent enzymes such as TET2, resulting in the loss of 5hmC, an increase in DNA methylation and ultimately altered gene expression programmes that drive cancer development66.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [66]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [173]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationXu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
Self-citationFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Self-citationIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
ATP-citrate lyase links cellular metabolism to histone acetylation
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1164097 · Cited by 2,298
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,001
The role of enhancers in cancer
Sur, I., & Taipale, J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.62 · Cited by 393
The implications of IDH mutations for cancer development and therapy
Pirozzi, C. J., & Yan, H. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00521-0 · Cited by 417
Oldham, W. M., Clish, C. B., Yang, Y., & Loscalzo, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.021 · Cited by 364
“These data support an alternative mechanism for HIF stabilization beyond direct PHD inhibition by 2HG.”
InfluentialRoboz, G. J., Dinardo, C. D., Stein, E. M., de Botton, S., Mims, A. S., Prince, G. T., Altman, J. K., Arellano, M. L., Donnellan, W., Erba, H. P., et al. (2019) · Blood · doi:10.1182/blood.2019002140 · Cited by 397
Gritsch, S., Batchelor, T. T., & Castro, L. N. G. (2021) · Cancer · doi:10.1002/cncr.33918 · Cited by 406
Understanding metabolic regulation and its influence on cell physiology
Metallo, C. M., & Vander Heiden, M. G. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.018 · Cited by 367
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Pan, M., Reid, M. A., Lowman, X. H., Kulkarni, R. P., Tran, T. Q., Liu, X., Yang, Y., Hernandez-Davies, J. E., Rosales, K. K., Li, H., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3410 · Cited by 368
The Significance of Mitochondrial Dysfunction in Cancer
Luo, Y., Ma, J., & Lu, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165598 · Cited by 380
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 377
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Amatangelo, M. D., Quek, L. S., Shih, A. H., Stein, E. M., Roshal, M., David, M. D., Marteyn, B., Farnoud, N. R., de Botton, S., Bernard, O., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779447 · Cited by 358
Self-citationClinical and Therapeutic Implications of Cancer Stem Cells
Clarke, M. F. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1804280 · Cited by 355
Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets
Bi, J., Chowdhry, S., Wu, S., Zhang, W., Masui, K., & Mischel, P. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0226-5 · Cited by 359
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D. L. P., Helgason, G. V., & Copland, M. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 365
The landscape of the mesenchymal signature in brain tumours
Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 357
Prognostic and Predictive Biomarkers in Gliomas
Śledzińska, P., Bebyn, M. G., Furtak, J., Kowalewski, J., & Lewandowska, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910373 · Cited by 363
Transcriptional and epigenetic control of brown and beige adipose cell fate and function
Inagaki, T., Sakai, J., & Kajimura, S. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.62 · Cited by 347
Metabolic signaling in T cells
Shyer, J. A., Flavell, R. A., & Bailis, W. (2020) · Cell Research · doi:10.1038/s41422-020-0379-5 · Cited by 346
Genomics-Driven Oncology: Framework for an Emerging Paradigm
Garraway, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8934 · Cited by 343
Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Waitkus, M. S., Diplas, B. H., & Yan, H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.011 · Cited by 342
Metabolic Regulation of Histone Post-Translational Modifications
Fan, J., Krautkramer, K. A., Feldman, J. L., & Denu, J. M. (2015) · ACS Chemical Biology · doi:10.1021/cb500846u · Cited by 339
Finley, L. W. S. (2023) · Cell · doi:10.1016/j.cell.2023.01.038 · Cited by 343
The Glioma Stem Cell Model in the Era of Single-Cell Genomics
Suvà, M. L., & Tirosh, I. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.001 · Cited by 334
Metabolic signatures of cancer cells and stem cells
Intlekofer, A. M., & Finley, L. W. S. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0032-0 · Cited by 322
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
DiNardo, C. D., Ravandi, F., Agresta, S., Konopleva, M., Takahashi, K., Kadia, T., Routbort, M., Patel, K. P., Brandt, M., Pierce, S., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24072 · Cited by 325
The 2016 World Health Organization classification of tumours of the central nervous system
Villa, C., Miquel, C., Mosses, D., Bernier, M., & Stefano, A. L. D. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.04.015 · Cited by 322
Keating, S. T., & El‐Osta, A. (2015) · Circulation Research · doi:10.1161/circresaha.116.303936 · Cited by 324
Kickingereder, P., Sahm, F., Radbruch, A., Wick, W., Heiland, S., von Deimling, A., Bendszus, M., & Wiestler, B. (2015) · Scientific Reports · doi:10.1038/srep16238 · Cited by 318
Oncometabolites suppress DNA repair by disrupting local chromatin signalling
Sulkowski, P. L., Oeck, S., Dow, J., Economos, N. G., Mirfakhraie, L., Liu, Y., Noronha, K. J., Bao, X., Li, J., Shuch, B. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2363-0 · Cited by 311
Towards precision medicine for AML
Döhner, H., Wei, A. H., & Löwenberg, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00509-w · Cited by 319
Challenges for assessing replicability in preclinical cancer biology
Errington, T. M., Denis, A., Perfito, N., Iorns, E., & Nosek, B. A. (2021) · eLife · doi:10.7554/elife.67995 · Cited by 345
Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
Malta, T. M., de Souza, C. F., Sabedot, T. S., Silva, T. C., Mosella, M. S., Kalkanis, S. N., Snyder, J., Castro, A. V. B., & Noushmehr, H. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox183 · Cited by 302
Molecular biomarkers in acute myeloid leukemia
Prada‐Arismendy, J., Arroyave-Ospina, J. C., & Röthlisberger, S. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.08.005 · Cited by 317
Role of mitochondrial dysfunction in cancer progression
Hsu, C., Tseng, L., & Lee, H. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216641787 · Cited by 320
The Warburg Effect 97 Years after Its Discovery
Pascale, R. M., Calvisi, D. F., Simile, M. M., Feo, C. F., & Feo, F. (2020) · Cancers · doi:10.3390/cancers12102819 · Cited by 311
Mitochondrial DNA variation and cancer
Kopinski, P. K., Singh, L. N., Zhang, S., Lott, M. T., & Wallace, D. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00358-w · Cited by 301
Emerging roles for chromatin as a signal integration and storage platform
Badeaux, A. I., & Shi, Y. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3545 · Cited by 291
Akalin, A., Garrett-Bakelman, F. E., Kormaksson, M., Busuttil, J., Zhang, L., Khrebtukova, I., Milne, T. A., Huang, Y., Biswas, D., Hess, J. L., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002781 · Cited by 296
Self-citationSasaki, M., Knobbe, C. B., Itsumi, M., Elia, A. J., Harris, I. S., Chio, I. I. C., Cairns, R. A., McCracken, S., Wakeham, A., Haight, J., et al. (2012) · Genes & Development · doi:10.1101/gad.198200.112 · Cited by 296
The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence
Auffinger, B., Spencer, D. A., Pytel, P., Ahmed, A. U., & Lesniak, M. S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1051968 · Cited by 301
Fontebasso, A. M., Schwartzentruber, J., Khuong-Quang, D.-A., Liu, X.-Y., Sturm, D., Korshunov, A., Jones, D., Witt, H., Kool, M., Albrecht, S., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1095-8 · Cited by 303
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases
Solary, É., Bernard, O., Tefferi, A., Fuks, F., & Vainchenker, W. (2013) · Leukemia · doi:10.1038/leu.2013.337 · Cited by 298
Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells
Colwell, N. A., Larion, M., Giles, A. J., Seldomridge, A. N., Sizdahkhani, S., Gilbert, M. R., & Park, D. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now258 · Cited by 293
Isocitrate dehydrogenase mutations in gliomas
Waitkus, M. S., Diplas, B. H., & Yan, H. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov136 · Cited by 292
Grassian, A. R., Parker, S. J., Davidson, S. M., Divakaruni, A. S., Green, C. R., Zhang, X., Slocum, K. L., Pu, M., Lin, F., Vickers, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0772-t · Cited by 280
Epigenetics and Trained Immunity
van der Heijden, C. D. C. C., Noz, M. P., Joosten, L. A. B., Netea, M. G., Riksen, N. P., & Keating, S. T. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7310 · Cited by 295
Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kannan, K. S., Inagaki, A., Silber, J., Gorovets, D. J., Zhang, J., Kastenhuber, E. R., Heguy, A., Petrini, J. H. J., Chan, T. A.-T., & Huse, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.689 · Cited by 283
Self-citationPathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue
D’Alessio, A., Proietti, G., Sica, G., & Scicchitano, B. M. (2019) · Cancers · doi:10.3390/cancers11040469 · Cited by 289
Mellinghoff, I. K., Peñas-Prado, M., Peters, K. B., Burris, H. A., Maher, E. A., Jankú, F., Cote, G. M., de la Fuente, M. I., Clarke, J. L., Ellingson, B. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0611 · Cited by 291
Self-citationThe functional roles of TCA cycle metabolites in cancer
Eniafe, J., & Jiang, S. (2021) · Oncogene · doi:10.1038/s41388-020-01639-8 · Cited by 289
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A. C., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 283
Núñez, F. J., Mendez, F., Kadiyala, P., Alghamri, M. S., Savelieff, M. G., Garcia-Fabiani, M. B., Haase, S., Koschmann, C. J., Calinescu, A., Kamran, N., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1427 · Cited by 264
Self-citationL-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH
Intlekofer, A. M., Wang, B., Liu, H., Shah, H., Carmona-Fontaine, C., Rustenburg, A. S., Salah, S., Gunner, M. R., Chodera, J. D., Cross, J. R., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2307 · Cited by 268
Self-citationIm, A., Sehgal, A. R., Carroll, M. P., Smith, B. D., Tefferi, A., Johnson, D. E., & Boyiadzis, M. M. (2014) · Leukemia · doi:10.1038/leu.2014.124 · Cited by 278
Rampal, R. K., Akalin, A., Madžo, J., Vasanthakumar, A., Pronier, E., Patel, J. L., Li, Y., Ahn, J., Abdel-Wahab, O. I., Shih, A. H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.004 · Cited by 280
Self-citationConnections between TET proteins and aberrant DNA modification in cancer
Huang, Y., & Rao, A. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.07.005 · Cited by 274
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
Wong, C. C., Qian, Y., & Yu, J. Q. (2017) · Oncogene · doi:10.1038/onc.2016.485 · Cited by 266
Mazor, T., Pankov, A., Johnson, B., Hong, C., Hamilton, E. G., Bell, R. J. A., Smirnov, I. V., Reis, G. F., Phillips, J. J., Barnes, M. J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.012 · Cited by 270
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery
Santagata, S., Eberlin, L. S., Norton, I. H., Calligaris, D., Feldman, D. R., Ide, J. L., Liu, X., Wiley, J. S., Vestal, M. L., Ramkissoon, S. H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404724111 · Cited by 264
Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
Flavahan, W. A., Drier, Y., Johnstone, S. E., Hemming, M. L., Tarjan, D. R., Hegazi, E., Shareef, S. J., Javed, N. M., Raut, C. P., Eschle, B. K., et al. (2019) · Nature · doi:10.1038/s41586-019-1668-3 · Cited by 258
IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma
Wang, C., McKeithan, T. W., Gong, Q., Zhang, W., Bouska, A. C., Rosenwald, A., Gascoyne, R. D., Wu, X., Wang, J., Muhammad, Z., et al. (2015) · Blood · doi:10.1182/blood-2015-05-644591 · Cited by 256
Defects in mitochondrial metabolism and cancer
Gaude, E., & Frezza, C. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-10 · Cited by 266
TET proteins and the control of cytosine demethylation in cancer
Scourzic, L., Mouly, E., & Bernard, O. (2015) · Genome Medicine · doi:10.1186/s13073-015-0134-6 · Cited by 263
Targeting Epigenetics in Cancer
Bennett, R. L., & Licht, J. D. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105106 · Cited by 254
Miller, J. J., Castro, L. N. G., McBrayer, S. K., Weller, M., Cloughesy, T. F., Portnow, J., Andronesi, O. C., Barnholtz‐Sloan, J. S., Baumert, B. G., Berger, M. S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac207 · Cited by 265
Self-citationTricarboxylic Acid (TCA) Cycle Intermediates: Regulators of Immune Responses
Choi, I., Son, H., & Baek, J.-H. (2021) · Life · doi:10.3390/life11010069 · Cited by 262
Mellinghoff, I. K., Lu, M., Wen, P. Y., Taylor, J. W., Maher, E. A., Arrillaga‐Romany, I., Peters, K. B., Ellingson, B. M., Rosenblum, M. K., Chun, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02141-2 · Cited by 256
Self-citationCancer metabolism: Key players in metabolic reprogramming
Soga, T. (2012) · Cancer Science · doi:10.1111/cas.12085 · Cited by 247
Metabolic rearrangements in primary liver cancers: cause and consequences
Satriano, L., Lewińska, M., Rodrigues, P. M., Bañales, J. M., & Andersen, J. B. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0217-8 · Cited by 245
Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates
Ye, D., Guan, K.-L., & Xiong, Y. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.005 · Cited by 242
Wild-type and mutated IDH1/2 enzymes and therapy responses
Molenaar, R. J., Maciejewski, J. P., Wilmink, J. W., & Noorden, C. J. F. V. (2018) · Oncogene · doi:10.1038/s41388-017-0077-z · Cited by 249
Chang, S., Yim, S., & Park, H. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0230-6 · Cited by 228
Sorting out functions of sirtuins in cancer
Roth, M., & Chen, W. (2013) · Oncogene · doi:10.1038/onc.2013.120 · Cited by 242
Turcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240
Self-citationLi, F., He, X., Ye, D., Lin, Y., Yu, H., Yao, C., Huang, L., Zhang, J., Wang, F., Xu, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.017 · Cited by 244
TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer
Hua, W., ten Dijke, P., Kostidis, S., Giera, M. A., & Hornsveld, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03398-6 · Cited by 245
Metabolic regulation of chromatin modifications and gene expression
Schvartzman, J. M., Thompson, C. B., & Finley, L. W. S. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201803061 · Cited by 233
Self-citationMacLeod, G. D. A. H., Bozek, D., Rajakulendran, N., Monteiro, V., Ahmadi, M., Steinhart, Z., Kushida, M. M., Yu, H., Coutinho, F. J., Cavalli, F. M. G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2019.03.047 · Cited by 246
Venneti, S., Garimella, M., Sullivan, L. M., Martínez, D., Huse, J. T., Heguy, A., Santi, M., Thompson, C. B., & Judkins, A. R. (2013) · Brain Pathology · doi:10.1111/bpa.12042 · Cited by 249
Self-citationKalyanaraman, B., Cheng, G., Hardy, M., Ouari, O., López, M., Joseph, J., Zielonka, J., & Dwinell, M. B. (2017) · Redox Biology · doi:10.1016/j.redox.2017.09.020 · Cited by 239
Hematopoietic Stem Cell Metabolism during Development and Aging
Nakamura‐Ishizu, A., Ito, K., & Suda, T. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.06.029 · Cited by 245
2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling
Fu, X., Chin, R., Vergnes, L., Hwang, H., Deng, G., Xing, Y., Pai, M. Y., Li, S., Ta, L. H., Fazlollahi, F., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.009 · Cited by 230
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Wick, W., Meisner, C., Hentschel, B., Platten, M., Schilling, A., Wiestler, B., Sabel, M., Koeppen, S., Ketter, R., Weiler, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a95680 · Cited by 235
Stein, E. M., Dinardo, C. D., Fathi, A. T., Mims, A. S., Pratz, K. W., Savona, M. R., Stein, A. S., Stone, R. M., Winer, E. S., Seet, C. S., et al. (2020) · Blood · doi:10.1182/blood.2020007233 · Cited by 237
2-Oxoglutarate-dependent dioxygenases in cancer
Losman, J.-A., Koivunen, P., & Kaelin, W. G. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00303-3 · Cited by 241
Cancer Metabolism: Current Understanding and Therapies
Counihan, J. L., Grossman, E. A., & Nomura, D. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00775 · Cited by 236
The crucial role of multiomic approach in cancer research and clinically relevant outcomes
Lu, M., & Zhan, X. (2018) · The EPMA Journal · doi:10.1007/s13167-018-0128-8 · Cited by 235
Oligodendroglioma: pathology, molecular mechanisms and markers
Wesseling, P., van den Bent, M. J., & Perry, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1424-1 · Cited by 233
Harding, J. J., Lowery, M. A., Shih, A. H., Schvartzman, J. M., Hou, S., Famulare, C. A., Patel, M. A., Roshal, M., Do, R. K. G., Zehir, A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0877 · Cited by 238
Self-citationLowery, M. A., Burris, H. A., Jankú, F., Shroff, R. T., Cleary, J. M., Azad, N. S., Goyal, L., Maher, E. A., Gore, L., Hollebecque, A., et al. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30189-x · Cited by 223
Turkalp, Z. T., Karamchandani, J., & Das, S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1205 · Cited by 222
The interplay between DNA and histone methylation: molecular mechanisms and disease implications
Li, Y., Chen, X., & Lu, C. (2021) · The EMBO Reports · doi:10.15252/embr.202051803 · Cited by 223
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220
Oncometabolites in renal cancer
Yong, C., Stewart, G. D., & Frezza, C. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0210-z · Cited by 216
Chromatin signatures of cancerPreprint
Morgan, M. A., & Shilatifard, A. (2015) · Genes & Development · doi:10.1101/gad.255182.114 · Cited by 218
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence
Turcan, Ş., Makarov, V., Taranda, J., Wang, Y., Fabius, A. W. M., Wu, W., Zheng, Y., El-Amine, N., Haddock, S., Nanjangud, G. J., et al. (2017) · Nature Genetics · doi:10.1038/s41588-017-0001-z · Cited by 221
Self-citationPluripotent stem cell energy metabolism: an update
TeSlaa, T. A., & Teitell, M. A. (2014) · The EMBO Journal · doi:10.15252/embj.201490446 · Cited by 221
Immunometabolic circuits in trained immunity
Arts, R. J. W., Joosten, L. A. B., & Netea, M. G. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.09.002 · Cited by 228
Undercover: gene control by metabolites and metabolic enzymesPreprint
van der Knaap, J. A., & Verrijzer, C. P. (2016) · Genes & Development · doi:10.1101/gad.289140.116 · Cited by 222
Metadata
- Authors
- Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., Wellen, K. E., O’Rourke, D. M., Berger, S. L., Chan, T. A., Levine, R. L., Mellinghoff, I. K., & Thompson, C. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Pennsylvania (US)
- Weill Cornell Medicine (US)
- Corresponding author
- Thompson, Craig B.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 474-478
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3478770
- OpenAlex
- W2154313451
- Cited by
- 1,985
- References
- 30
- Citations by year
- 2026: 81 · 2025: 93 · 2024: 106 · 2023: 125 · 2022: 122 · 2021: 180 · 2020: 170 · 2019: 153 · 2018: 146 · 2017: 163 · 2016: 151 · 2015: 123 · 2014: 138 · 2013: 136 · 2012: 91
- FWCI
- 74.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- National Cancer Institute (R01CA078831, R01CA105463, U54CA143798)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- 2-hydroxyglutarate, histone demethylation, histone methylation, glioma, oncometabolites, DNA hypermethylation, hypoxia-inducible factor, adipogenesis, neural progenitor cells
- MeSH terms
- Animals, Astrocytes, Cell Differentiation, Enzyme Induction, Gene Expression Regulation, Glioma, Glutarates, Histones, Humans, Isocitrate Dehydrogenase, Methylation, Mutation, Promoter Regions, Genetic, Adipocytes, Cell Lineage, DNA Methylation, 3T3-L1 Cells, Cell Line, Tumor, Mice, Jumonji Domain-Containing Histone Demethylases, HEK293 Cells, Neural Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
